Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Expands Patented Drug Delivery Portfolio with New Breakthroughs
Novel drug delivery system scientifically proven to increase absorption, bioavailability and efficacy New U.S. patents awarded, strengthening company’s IP portfolio Wide variety of patent families with ranging applications Building off DehydraTECH™, its patented lipophilic drug delivery platform, Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has received another new Notice of Allowance from the United States Patent and Trademark Office that protects the company’s processes for making specific compositions of matter for enhanced cannabinoid delivery (http://cnw.fm/yN7AQ). This latest announcement comes on the heels of Lexaria’s March 22, 2018, press release that announced its receipt of a Notice of Allowance for the…